In Vitro Interactions of Antibiotics with Drugs Used in Chronic Diseases

Year 2021, Volume: 7 Issue: 2, 178 - 185, 31.08.2021

Esra Erdoğan , Selami Günal

https://doi.org/10.19127/mbsjohs.817255

Abstract

Objective: In this century, with the prolonged life expectancy, chronic diseases have become the most important cause of mortality and morbidity in the world and in our country. Frequent drug-drug interactions have made it necessary to update the doses of drugs in multiple drug use. In our study, we aimed to observe how the drugs that are frequently prescribed by physicians in the treatment of chronic and infectious diseases, together with standard bacteria and fungi strains in in vitro environment, change the effects of each other.
Methods: By combining antibiotic discs and drugs that are commonly used in chronic diseases (acetylsalicylic acid, amlodipine, atorvastatin, warfarin, metoprolol and clopidogrel) in in vitro environment, we determined the drug interactions (synergy/antagonism) by Kirby Bauer disk diffusion method.
Results: While most of the discs placed on the culture of Candida albicans through impregnation of drugs showed potentiation synergism with itraconazole and fluconazole, other microorganisms showed synergistic and sometimes antagonistic interactions with different drugs and antibiotics, whereas some of the drugs did not show any interaction with antibiotic discs.
Conclusion: Due to the strong relationship between advanced age and the number of prescribed drugs and the frequency of possible drug-drug interactions, the elderly people especially are susceptible to this situation. Infections caused by resistant bacteria cause an increase in disease/death rates and treatment costs. With the awareness that the only difference between drug and poison is the dose, all health professionals especially doctors and pharmacists and patients have a responsibility towards the rational use of drugs.

Keywords

antibiotics, chronic diseases, disk diffusion method, drug interactions

Project Number

TDK-2018-1376

References

• 1. World Health Organization. Major NCDs and their risk factors 2018. https://www.who.int/ncds/introduction/en/ 23 Mart 2019.
• 1. World Health Organization. Major NCDs and their risk factors 2018. https://www.who.int/ncds/introduction/en/ 23 Mart 2019.
• 2. World Health Organization. Natıonal Household Health Survey in Turkey Prevalence of Noncommunıcable Disease Factors 2017. https://www.who.int/ncds/surveillance/steps/WHO_Turkey_Risk_Factors_A4_TR_19.06.2018.pdf 24 Mart 2019.
• 2. World Health Organization. Natıonal Household Health Survey in Turkey Prevalence of Noncommunıcable Disease Factors 2017. https://www.who.int/ncds/surveillance/steps/WHO_Turkey_Risk_Factors_A4_TR_19.06.2018.pdf 24 Mart 2019.
• 3. Snyder BD, Polasek TM, Doogue MP. Drug interactions: principles and practice. Aust Prescr.2012, 35: 85-8.
• 3. Snyder BD, Polasek TM, Doogue MP. Drug interactions: principles and practice. Aust Prescr.2012, 35: 85-8.
• 4. Stepanović S, Vuković D, Ješić M, Ranin L. Influence of acetylsalicylic acid (aspirin) on biofilm production by Candida species. J Chemother 2004, 16: 134-8.
• 4. Stepanović S, Vuković D, Ješić M, Ranin L. Influence of acetylsalicylic acid (aspirin) on biofilm production by Candida species. J Chemother 2004, 16: 134-8.
• 5. T.R. Ministry of Health. Yearbook of Health Statistics. Ankara 2016. https://dosyasb.saglik.gov.tr/Eklenti/13183,sy2016turkcepdf.pdf24 Mart 2019.
• 5. T.R. Ministry of Health. Yearbook of Health Statistics. Ankara 2016. https://dosyasb.saglik.gov.tr/Eklenti/13183,sy2016turkcepdf.pdf24 Mart 2019.
• 6. Clinical and Laboratory Standards Institute (CLSI), Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard 13th Edition. CLSI Document, M02Ed13E, 1-56238-834-7 M022018.Clinical and Laboratory Standards Institute 950 West Valley Road, Suite 2500 Wayne, PA 19087 USA.
• 6. Clinical and Laboratory Standards Institute (CLSI), Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard 13th Edition. CLSI Document, M02Ed13E, 1-56238-834-7 M022018.Clinical and Laboratory Standards Institute 950 West Valley Road, Suite 2500 Wayne, PA 19087 USA.
• 7. Clinical and Laboratory Standards Institute (CLSI), Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard 11th Edition. CLSI Document, M02Ed13E, 1-56238-834-7M07 2018. Clinical and Laboratory Standards Institute 950 West Valley Road, Suite 2500 Wayne, PA 19087 USA. 8. Clinical and Laboratory Standards Institute (CLSI), Performance Standards for Antifungal Susceptibility Testing of Yeast. 1st ed. CLSI supplement M60.2018. Clinical and Laboratory Standards Institute 950 West Valley Road, Suite 2500 Wayne, PA 19087 USA
• 7. Clinical and Laboratory Standards Institute (CLSI), Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard 11th Edition. CLSI Document, M02Ed13E, 1-56238-834-7M07 2018. Clinical and Laboratory Standards Institute 950 West Valley Road, Suite 2500 Wayne, PA 19087 USA. 8. Clinical and Laboratory Standards Institute (CLSI), Performance Standards for Antifungal Susceptibility Testing of Yeast. 1st ed. CLSI supplement M60.2018. Clinical and Laboratory Standards Institute 950 West Valley Road, Suite 2500 Wayne, PA 19087 USA
• 9. Beggi B. Rational Drug Use and Polypharmacy Approach in Family Medicine. Antalya Health Practice and Research Center, Family Medicine Clinic. PhD thesis, Antalya: University of Health Sciences, 2018.
• 9. Beggi B. Rational Drug Use and Polypharmacy Approach in Family Medicine. Antalya Health Practice and Research Center, Family Medicine Clinic. PhD thesis, Antalya: University of Health Sciences, 2018.
• 10. Koroglu AL. Investigation of drug interactions and dose overconnections in geriatric patient prepaids. Institute of Health Sciences, Department of Clinical Pharmacy. Master Thesis, Istanbul: Istanbul Medipol University, 2018.
• 10. Koroglu AL. Investigation of drug interactions and dose overconnections in geriatric patient prepaids. Institute of Health Sciences, Department of Clinical Pharmacy. Master Thesis, Istanbul: Istanbul Medipol University, 2018.
• 11. Miró-Canturri A, Ayerbe-Algaba R, Smani Y. Drug repurposing for the treatment of bacterial and fungal infections. Front Microbiol 2019, 10: 41.
• 11. Miró-Canturri A, Ayerbe-Algaba R, Smani Y. Drug repurposing for the treatment of bacterial and fungal infections. Front Microbiol 2019, 10: 41.
• 12. Younis W, Thangamani S, MN S. Repurposing non-antimicrobial drugs and clinical molecules to treat bacterial infections. Curr Pharm Des 2015, 21: 4106-11.
• 12. Younis W, Thangamani S, MN S. Repurposing non-antimicrobial drugs and clinical molecules to treat bacterial infections. Curr Pharm Des 2015, 21: 4106-11.
• 13. Zimmermann P, Curtis N. Antimicrobial effects of antipyretics. Antimicrob Agents Chemother 2017, 61: 1-12.
• 13. Zimmermann P, Curtis N. Antimicrobial effects of antipyretics. Antimicrob Agents Chemother 2017, 61: 1-12.
• 14. Laudy AE, Mrowka A, Krajewska J, Tyski S. The influence of efflux pump inhibitors on the activity of non-antibiotic NSAIDS against gram-negative rods. PloS One 2016, 11: 1-16.
• 14. Laudy AE, Mrowka A, Krajewska J, Tyski S. The influence of efflux pump inhibitors on the activity of non-antibiotic NSAIDS against gram-negative rods. PloS One 2016, 11: 1-16.
• 15. Repaske DR, Adler J. Change in intracellular pH of Escherichia coli mediates the chemotactic response to certain attractants and repellents. J Bacteriol 1981, 145: 1196-208.
• 15. Repaske DR, Adler J. Change in intracellular pH of Escherichia coli mediates the chemotactic response to certain attractants and repellents. J Bacteriol 1981, 145: 1196-208.
• 16. Rosner JL. Nonheritable resistance to chloramphenicol and other antibiotics induced by salicylates and other chemotactic repellents in Escherichia coli K-12. Proc Natl Acad Sci USA 1985, 82: 8771-4.
• 16. Rosner JL. Nonheritable resistance to chloramphenicol and other antibiotics induced by salicylates and other chemotactic repellents in Escherichia coli K-12. Proc Natl Acad Sci USA 1985, 82: 8771-4.
• 17. Aumercier M, Murray DM, Rosner JL. Potentiation of susceptibility to aminoglycosides by salicylate in Escherichia coli. Antimicrob Agents Chemother 1990, 34: 786-91.
• 17. Aumercier M, Murray DM, Rosner JL. Potentiation of susceptibility to aminoglycosides by salicylate in Escherichia coli. Antimicrob Agents Chemother 1990, 34: 786-91.
• 18. El-Mowafy SA, Abd El Galil KH, El-Messery SM, Shaaban MI. Aspirin is an efficient inhibitor of quorum sensing, virulence and toxins in Pseudomonas aeruginosa. Microb pathog 2014, 74: 25-32. 19. Bandara M, Sankaridurg P, Zhu H, Hume E, Willcox M. Effect of salicylic acid on the membrane proteome and virulence of Pseudomonas aeruginosa. Invest Ophthalmol Vis Sci 2016, 57: 1213-20.
• 18. El-Mowafy SA, Abd El Galil KH, El-Messery SM, Shaaban MI. Aspirin is an efficient inhibitor of quorum sensing, virulence and toxins in Pseudomonas aeruginosa. Microb pathog 2014, 74: 25-32. 19. Bandara M, Sankaridurg P, Zhu H, Hume E, Willcox M. Effect of salicylic acid on the membrane proteome and virulence of Pseudomonas aeruginosa. Invest Ophthalmol Vis Sci 2016, 57: 1213-20.
• 20. Bazyleu A, Kumar A. Incubation temperature, osmolarity, and salicylate affect the expression of resistance–nodulation–division efflux pumps and outer membrane porins in Acinetobacter baumannii ATCC19606T. FEMS Microbiol Lett 2014, 357: 136-43.
• 20. Bazyleu A, Kumar A. Incubation temperature, osmolarity, and salicylate affect the expression of resistance–nodulation–division efflux pumps and outer membrane porins in Acinetobacter baumannii ATCC19606T. FEMS Microbiol Lett 2014, 357: 136-43.
• 21. Domenico P, Hopkins T, Cunha BA. The effect of sodium salicylate on antibiotic susceptibility and synergy in Klebsiella pneumoniae. J Antimicrob Chemother 1990, 26: 343-51.
• 21. Domenico P, Hopkins T, Cunha BA. The effect of sodium salicylate on antibiotic susceptibility and synergy in Klebsiella pneumoniae. J Antimicrob Chemother 1990, 26: 343-51.
• 22. Chan EWL, Yee ZY, Raja I, Yap JKY. Synergistic effect of non-steroidal anti-inflammatory drugs (NSAIDs) on antibacterial activity of cefuroxime and chloramphenicol against methicillin-resistant Staphylococcus aureus. J Glob Antimicrob Resist 2017, 10: 70-4.
• 22. Chan EWL, Yee ZY, Raja I, Yap JKY. Synergistic effect of non-steroidal anti-inflammatory drugs (NSAIDs) on antibacterial activity of cefuroxime and chloramphenicol against methicillin-resistant Staphylococcus aureus. J Glob Antimicrob Resist 2017, 10: 70-4.
• 23. Gustafson JE, Candelaria PV, Fisher SA, Goodridge JP, Lichocik TM, McWilliams TM, et al. Growth in the presence of salicylate increases fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1999, 43: 990-2.
• 23. Gustafson JE, Candelaria PV, Fisher SA, Goodridge JP, Lichocik TM, McWilliams TM, et al. Growth in the presence of salicylate increases fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1999, 43: 990-2.
• 24. Alem MA, Douglas LJ. Effects of aspirin and other nonsteroidal anti-inflammatory drugs on biofilms and planktonic cells of Candida albicans. Antimicrob Agents Chemother 2004, 48: 41-7.
• 24. Alem MA, Douglas LJ. Effects of aspirin and other nonsteroidal anti-inflammatory drugs on biofilms and planktonic cells of Candida albicans. Antimicrob Agents Chemother 2004, 48: 41-7.
• 25. Zhou Y, Wang G, Li Y, Liu Y, Song Y, Zheng W, et al. In vitro interactions between aspirin and amphotericin B against planktonic cells and biofilm cells of Candida albicans and C. parapsilosis. Antimicrob Agents Chemother 2012, 56: 3250-60.
• 25. Zhou Y, Wang G, Li Y, Liu Y, Song Y, Zheng W, et al. In vitro interactions between aspirin and amphotericin B against planktonic cells and biofilm cells of Candida albicans and C. parapsilosis. Antimicrob Agents Chemother 2012, 56: 3250-60.
• 26. Krajewska-Kułak E, Niczyporuk W. Effects of the combination of ketoconazole and calcium channel antagonists against Candida albicans in vitro. Arzneimittel-Forschung 1993, 43: 782-3.
• 26. Krajewska-Kułak E, Niczyporuk W. Effects of the combination of ketoconazole and calcium channel antagonists against Candida albicans in vitro. Arzneimittel-Forschung 1993, 43: 782-3.
• 27. Liu S, Yue L, Gu W, Li X, Zhang L, Sun S. Synergistic effect of fluconazole and calcium channel blockers against resistant Candida albicans. PLoS One 2016, 11: 1-12.
• 27. Liu S, Yue L, Gu W, Li X, Zhang L, Sun S. Synergistic effect of fluconazole and calcium channel blockers against resistant Candida albicans. PLoS One 2016, 11: 1-12.
• 28. Hu C, Li Y, Zhao Z, Wei S, Zhao Z, Chen H, et al. In vitro synergistic effect of amlodipine and imipenem on the expression of the AdeABC efflux pump in multidrug-resistant Acinetobacter baumannii. PloS One 2018, 13: 1-11. 29. Li Yj, Pan Cz, Zhao Zw, Zhao Zx, Chen Hl, Lu Wb. Effects of a combination of amlodipine and imipenem on 42 clinical isolates of Acinetobacter baumannii obtained from a teaching hospital in Guangzhou, China. BMC Infect Dis 2013, 13: 1-9.
• 28. Hu C, Li Y, Zhao Z, Wei S, Zhao Z, Chen H, et al. In vitro synergistic effect of amlodipine and imipenem on the expression of the AdeABC efflux pump in multidrug-resistant Acinetobacter baumannii. PloS One 2018, 13: 1-11. 29. Li Yj, Pan Cz, Zhao Zw, Zhao Zx, Chen Hl, Lu Wb. Effects of a combination of amlodipine and imipenem on 42 clinical isolates of Acinetobacter baumannii obtained from a teaching hospital in Guangzhou, China. BMC Infect Dis 2013, 13: 1-9.
• 30. Hennessy E, Mooij MJ, Legendre C, Reen FJ, O'Callaghan J, Adams C, et al. Statins inhibit in vitro virulence phenotypes of Pseudomonas aeruginosa. J Antibiot (Tokyo) 2013, 66: 99-101.
• 30. Hennessy E, Mooij MJ, Legendre C, Reen FJ, O'Callaghan J, Adams C, et al. Statins inhibit in vitro virulence phenotypes of Pseudomonas aeruginosa. J Antibiot (Tokyo) 2013, 66: 99-101.
• 31. Kruszewska H, Zareba T, Tyski S. Examination of antibacterial and antifungal activity of selected non-antibiotic products. Act Pol Pharm Drug Res 2008, 65: 779-82.
• 31. Kruszewska H, Zareba T, Tyski S. Examination of antibacterial and antifungal activity of selected non-antibiotic products. Act Pol Pharm Drug Res 2008, 65: 779-82.
• 32. Chen W, Wu T, Jiang S, Lv M, Fu J, Xia X, Zhang J. Clinical analysis of the effects of azole antifungal agents on the anticoagulant activity of warfarin. Medicine (Baltimore). 2020 Nov 13;99(46):e22987. doi: 10.1097/MD.0000000000022987.
• 32. Chen W, Wu T, Jiang S, Lv M, Fu J, Xia X, Zhang J. Clinical analysis of the effects of azole antifungal agents on the anticoagulant activity of warfarin. Medicine (Baltimore). 2020 Nov 13;99(46):e22987. doi: 10.1097/MD.0000000000022987.
• 33. Lima WG, Alves-Nascimento LA, Andrade JT, Vieira L, de Azambuja Ribeiro RIM, Thomé RG, Dos Santos HB, Ferreira JMS, Soares AC. Are the Statins promising antifungal agents against invasive candidiasis? Biomed Pharmacother. 2019 Mar;111:270-281. doi: 10.1016/j.biopha.2018.12.076.
• 33. Lima WG, Alves-Nascimento LA, Andrade JT, Vieira L, de Azambuja Ribeiro RIM, Thomé RG, Dos Santos HB, Ferreira JMS, Soares AC. Are the Statins promising antifungal agents against invasive candidiasis? Biomed Pharmacother. 2019 Mar;111:270-281. doi: 10.1016/j.biopha.2018.12.076.